Financials MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
4.23 USD +1.20% Intraday chart for MannKind Corporation +1.20% +16.21%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 266.3 728 1,098 1,387 981.3 1,145 - -
Enterprise Value (EV) 1 266.3 728 1,098 1,387 679 897 872.7 820.7
P/E ratio -4.78 x -12 x -13.7 x -15.5 x -91 x 32 x 18.5 x 11 x
Yield - - - - - - - -
Capitalization / Revenue 4.22 x 11.2 x 14.6 x 13.9 x 4.93 x 4.41 x 3.66 x 3.03 x
EV / Revenue 4.22 x 11.2 x 14.6 x 13.9 x 3.41 x 3.45 x 2.79 x 2.17 x
EV / EBITDA - - - - - - - -
EV / FCF - - - - -81.3 x 4.77 x 6.93 x 4.91 x
FCF Yield - - - - -1.23% 21% 14.4% 20.3%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 206,408 232,601 251,256 263,196 269,575 270,763 - -
Reference price 2 1.290 3.130 4.370 5.270 3.640 4.230 4.230 4.230
Announcement Date 2/25/20 2/25/21 2/24/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 63.04 65.14 75.44 99.77 199 259.9 312.8 377.8
EBITDA - - - - - - - -
EBIT 1 -44.6 -34.68 -47.02 -64.11 8.678 64.13 96.81 150
Operating Margin -70.75% -53.24% -62.33% -64.26% 4.36% 24.67% 30.95% 39.69%
Earnings before Tax (EBT) 1 -51.9 -57.46 -80.93 -87.4 -10.38 43.03 78.31 138.6
Net income 1 -51.9 -57.24 -80.93 -87.4 -11.94 38.84 73.61 124.7
Net margin -82.34% -87.87% -107.27% -87.6% -6% 14.94% 23.53% 33.01%
EPS 2 -0.2700 -0.2600 -0.3200 -0.3400 -0.0400 0.1320 0.2283 0.3840
Free Cash Flow 1 - - - - -8.347 188 126 167
FCF margin - - - - -4.2% 72.32% 40.28% 44.2%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - 483.99% 171.17% 133.89%
Dividend per Share - - - - - - - -
Announcement Date 2/25/20 2/25/21 2/24/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 22.21 12.52 11.99 18.89 32.82 36.06 40.63 48.61 51.25 58.47 60.55 63.64 66.38 69.35
EBITDA - - - - - - - - - - - - - -
EBIT 1 -6.59 -23.97 -21.26 -20.45 -9.61 -12.79 -5.998 1.721 5.097 7.858 13.92 15.22 16.66 18.08
Operating Margin -29.67% -191.51% -177.25% -108.26% -29.28% -35.47% -14.76% 3.54% 9.94% 13.44% 22.99% 23.92% 25.1% 26.07%
Earnings before Tax (EBT) 1 -4.426 -28.06 -26 -29.02 -14.43 -17.95 -9.795 -5.265 1.721 2.962 8.805 9.78 11.6 12.85
Net income 1 -4.426 -28.06 -26 -29.02 -14.43 -17.95 -9.795 -5.265 1.721 1.401 7.754 8.56 10.23 12.3
Net margin -19.93% -224.22% -216.79% -153.61% -43.97% -49.77% -24.11% -10.83% 3.36% 2.4% 12.81% 13.45% 15.41% 17.74%
EPS 2 -0.0200 -0.1100 -0.1000 -0.1100 -0.0600 -0.0700 -0.0400 -0.0200 0.0100 0.004300 0.0260 0.0300 0.0340 0.0420
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/9/21 2/24/22 5/5/22 8/9/22 11/8/22 2/23/23 5/9/23 8/7/23 11/7/23 2/27/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - - 302 248 273 325
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - -8.35 188 126 167
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 2.57 0.8 11.5 7.59 42.4 11 14 18
Capex / Sales 4.07% 1.23% 15.2% 7.61% 21.33% 4.23% 4.48% 4.76%
Announcement Date 2/25/20 2/25/21 2/24/22 2/23/23 2/27/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.23 USD
Average target price
7.083 USD
Spread / Average Target
+67.45%
Consensus
  1. Stock Market
  2. Equities
  3. MNKD Stock
  4. Financials MannKind Corporation